These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22555080)

  • 1. Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.
    James C; Preininger L; Sweet M
    Am J Health Syst Pharm; 2012 May; 69(10):857-61. PubMed ID: 22555080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rilpivirine. First-line treatment of HIV infection: efavirenz is better documented.
    Prescrire Int; 2012 Nov; 21(132):262-5. PubMed ID: 23210255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanism of action and pharmacokinetics of rilpivirine].
    Portilla J; Estrada V
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():2-5. PubMed ID: 24252527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.
    Schafer JJ; Short WR
    Antivir Ther; 2012; 17(8):1495-502. PubMed ID: 22878339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor.
    Sharma M; Saravolatz LD
    J Antimicrob Chemother; 2013 Feb; 68(2):250-6. PubMed ID: 23099850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.
    Molina JM; Clumeck N; Orkin C; Rimsky LT; Vanveggel S; Stevens M;
    HIV Med; 2014 Jan; 15(1):57-62. PubMed ID: 23980523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy.
    Imaz A; Podzamczer D
    AIDS Rev; 2012; 14(4):268-78. PubMed ID: 23258301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
    Crauwels H; van Heeswijk RP; Stevens M; Buelens A; Vanveggel S; Boven K; Hoetelmans R
    AIDS Rev; 2013; 15(2):87-101. PubMed ID: 23681436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
    Fulco PP; McNicholl IR
    Pharmacotherapy; 2009 Mar; 29(3):281-94. PubMed ID: 19249947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rilpivirine: a new addition to the anti-HIV-1 armamentarium.
    Miller CD; Crain J; Tran B; Patel N
    Drugs Today (Barc); 2011 Jan; 47(1):5-15. PubMed ID: 21373646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor.
    Garvey L; Winston A
    Expert Opin Investig Drugs; 2009 Jul; 18(7):1035-41. PubMed ID: 19548857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Resistance profile of rilpivirine].
    Imaz A; García F; di Yacovo S; Llibre JM
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological properties of rilpivirine (Edurant Tablet), a new drug for the treatment of HIV, and results of its clinical studies].
    Iwata M; Shikinami K; Nagino K; Harada Y
    Nihon Yakurigaku Zasshi; 2013 Apr; 141(4):205-11. PubMed ID: 23575426
    [No Abstract]   [Full Text] [Related]  

  • 17. Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.
    Molina JM; Clumeck N; Redant K; Rimsky L; Vanveggel S; Stevens M;
    AIDS; 2013 Mar; 27(6):889-897. PubMed ID: 23276806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.
    Rokx C; Verbon A; Rijnders BJ
    HIV Med; 2014 Nov; 15(10):611-4. PubMed ID: 24738660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis.
    Li SL; Xu P; Zhang L; Sun GX; Lu ZJ
    HIV Clin Trials; 2014; 15(6):261-8. PubMed ID: 25433665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.